Shire LLC

New River Pharmaceuticals Inc.

Oravax, Inc.

James Scott Moncrief

Travis C Mickle

Suma Krishnan

Christopher Lauderback

Thomas Piccariello

Barney Bishop

Bernhard J Paul

Christopher Verbicky

Robert A Oberlender

Rob Oberlender

Sven Guenther

Sanjib Bera

Christal Mickle

Randal Kirk

Nancy Johnston Boerth

Wendy Hirschelman

Thomas P Monath

David Maxwell Lyerly

Zhenxi Zhang

Wende Lei

Lawrence Peter Olon

William D Thomas

Christal Miller

Alex Saunders Goldstein

Francisco Javier Torres-Lopez

Christopher A Verbicky

The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Active agent delivery systems and methods for protecting and administering active agents

The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

Pharmaceutical compositions for prevention of overdose or abuse

The invention provides a 'street-safe' version of a controlled substance that permits the therapeutically beneficial effects of the substance while reducing or eliminating the euphoric effects that lead to substance abuse. The invention provides pharmaceutical compositions comprising a controlled substance and a carbohydrate covalently bound to said controlled substance in a manner that renders said controlled substance pharmacologically inactive or substantially diminishes its activity and methods of using the same.

Carbohydrate conjugates to prevent abuse of controlled substances

The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction.

Compounds and compositions for prevention of overdose of oxycodone

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Abuse-resistant amphetamine prodrugs

Growing community of inventors

Christiansburg, VA, United States of America

James Scott Moncrief